Cairo Cure Oncology Center, Cairo, Egypt.
Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico.
J Clin Oncol. 2024 Aug 10;42(23):2822-2832. doi: 10.1200/JCO.23.02292. Epub 2024 May 29.
We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor-positive breast cancer (BC) desiring future pregnancy.
POSITIVE is an international, single-arm, prospective trial, in which 518 women temporarily interrupted adjuvant endocrine therapy to attempt pregnancy. We evaluated menstruation recovery and factors associated with time to pregnancy and investigated if ART use was associated with achieving pregnancy. The cumulative incidence of BC-free interval (BCFI) events was estimated according to the use of ovarian stimulation at diagnosis. The median follow-up was 41 months.
Two hundred seventy-three patients (53%) reported amenorrhea at enrollment, of whom 94% resumed menses within 12 months. Among 497 patients evaluable for pregnancy, 368 (74%) reported at least one pregnancy. Young age was the main factor associated with shorter time to pregnancy with cumulative incidences of pregnancy by 1 year of 63.5%, 54.3%, and 37.7% for patients age <35, 35-39, and 40-42 years, respectively. One hundred and seventy-nine patients (36%) had embryo/oocyte cryopreservation at diagnosis, of whom 68 reported embryo transfer after enrollment. Cryopreserved embryo transfer was the only ART associated with higher chance of pregnancy (odds ratio, 2.41 [95% CI, 1.75 to 4.95]). The cumulative incidence of BCFI events at 3 years was similar for women who underwent ovarian stimulation for cryopreservation at diagnosis, 9.7% (95% CI, 6.0 to 15.4), compared with those who did not, 8.7% (95% CI, 6.0 to 12.5).
In POSITIVE, fertility preservation using ovarian stimulation was not associated with short-term detrimental impact on cancer prognosis. Pregnancy rates were highest among those who underwent embryo/oocyte cryopreservation followed by embryo transfer.
我们研究了希望未来妊娠的早期激素受体阳性乳腺癌(BC)且有生育保存需求的女性的妊娠时间、生育保存效果和安全性,以及辅助生殖技术(ART)。
POSITIVE 是一项国际性、单臂、前瞻性试验,共纳入 518 例暂时中断辅助内分泌治疗以尝试妊娠的女性。我们评估了月经恢复情况和与妊娠时间相关的因素,并研究了使用 ART 是否与妊娠成功相关。根据诊断时是否进行卵巢刺激,估计无乳腺癌间隔(BCFI)事件的累积发生率。中位随访时间为 41 个月。
273 例患者(53%)入组时报告闭经,其中 94%在 12 个月内恢复月经。在 497 例可评估妊娠的患者中,368 例(74%)报告至少一次妊娠。年轻是与妊娠时间较短相关的主要因素,年龄<35 岁、35-39 岁和 40-42 岁的患者在 1 年内妊娠的累积发生率分别为 63.5%、54.3%和 37.7%。179 例患者(36%)在诊断时进行了胚胎/卵母细胞冷冻保存,其中 68 例在入组后进行了胚胎移植。冷冻保存胚胎移植是唯一与更高妊娠机会相关的 ART(优势比,2.41 [95%CI,1.75 至 4.95])。诊断时进行卵巢刺激以进行冷冻保存的患者与未进行卵巢刺激的患者相比,3 年内 BCFI 事件的累积发生率相似,分别为 9.7%(95%CI,6.0 至 15.4)和 8.7%(95%CI,6.0 至 12.5)。
在 POSITIVE 中,使用卵巢刺激的生育保存并未对癌症预后产生短期不利影响。妊娠率最高的是那些进行了胚胎/卵母细胞冷冻保存并随后进行胚胎移植的患者。